0.00Open0.00Pre Close0 Volume0 Open Interest130.00Strike Price0.00Turnover135.79%IV-44.51%PremiumJan 17, 2025Expiry Date104.28Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9937Delta0.0003Gamma2.24Leverage Ratio-0.0538Theta0.0432Rho2.22Eff Leverage0.0077Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet